Cantor Fitzgerald Reaffirms Neutral Rating for bluebird bio (NASDAQ:BLUE)

Cantor Fitzgerald restated their neutral rating on shares of bluebird bio (NASDAQ:BLUE) in a report published on Monday, Benzinga reports. Cantor Fitzgerald also issued estimates for bluebird bio’s FY2024 earnings at ($1.31) EPS.

Several other research firms have also issued reports on BLUE. Bank of America reduced their price target on shares of bluebird bio from $4.00 to $3.00 and set a buy rating on the stock in a research report on Thursday, August 15th. Royal Bank of Canada reissued a sector perform rating and set a $4.00 price target on shares of bluebird bio in a report on Thursday, August 15th. JPMorgan Chase & Co. lowered bluebird bio from an overweight rating to a neutral rating in a research note on Thursday, August 15th. Barclays lowered their target price on bluebird bio from $8.00 to $4.00 and set an overweight rating for the company in a research note on Thursday, August 15th. Finally, Robert W. Baird dropped their target price on shares of bluebird bio from $7.00 to $6.00 and set an outperform rating for the company in a report on Thursday, August 15th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, bluebird bio presently has a consensus rating of Hold and an average price target of $4.74.

bluebird bio Stock Performance

NASDAQ:BLUE opened at $0.50 on Monday. bluebird bio has a fifty-two week low of $0.48 and a fifty-two week high of $5.53. The company has a market cap of $54.12 million, a price-to-earnings ratio of -0.67 and a beta of 0.75. The stock has a fifty day moving average price of $0.86 and a 200-day moving average price of $1.00.

Institutional Investors Weigh In On bluebird bio

A number of institutional investors have recently added to or reduced their stakes in BLUE. Allegheny Financial Group LTD acquired a new stake in bluebird bio in the second quarter valued at $25,000. Dynamic Technology Lab Private Ltd bought a new stake in bluebird bio in the fourth quarter valued at approximately $37,000. Enterprise Bank & Trust Co acquired a new stake in bluebird bio during the 1st quarter valued at approximately $38,000. China Universal Asset Management Co. Ltd. raised its holdings in bluebird bio by 189.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 36,580 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 23,933 shares during the last quarter. Finally, Sequoia Financial Advisors LLC lifted its position in shares of bluebird bio by 48.0% in the 1st quarter. Sequoia Financial Advisors LLC now owns 40,085 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 13,000 shares during the period. 87.43% of the stock is owned by institutional investors.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.